Oculus Innovative Sciences Announces Fiscal Third Quarter 2011 Financial Results and Conference Call
PETALUMA, Calif.--(BUSINESS WIRE)--
Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), today announced that
the financial results for its fiscal third quarter 2011 ended December
31, 2010, will be released after the U.S. market closes on February 3,
2011. The earnings release will be followed by a conference call at 1:30
p.m. PT (4:30 p.m. ET) on February 3, 2011, to discuss fiscal third
Individuals interested in participating in the conference call may do so
by dialing 877-303-7020 for domestic callers or 973-409-9604 for
international callers. Those interested in listening to the conference
call live via the Internet may do so at http://ir.oculusis.com/events.cfm.
Please log on approximately 30 minutes prior to the presentation in
order to register and download the appropriate software.
A telephone replay will be available for 48 hours following the
conclusion of the call by dialing 800-642-1687 for domestic callers, or
706-645-9291 for international callers, and entering conference code
37947168. A webcast replay will be available on the site at http://ir.oculusis.com/events.cfm
for one year following the call.
About Oculus Innovative Sciences
Oculus Innovative Sciences is a commercial medical technology
company that designs, produces and markets safe and effective tissue
care products based upon the Microcyn® Technology platform, which
significantly reduces the need for antibiotics while reducing infections
and accelerating healing. The Microcyn Technology addresses the need for
improved solutions in multiple markets including dermatology, oral care,
cosmeceutical, wound care and others. It features a biocompatible,
shelf-stable solution that is currently commercialized in the United
States, Europe, India, China and Mexico and select Middle East countries
under various country specific regulatory clearances and approvals.
Several solutions derived from this platform have demonstrated, in a
variety of research and investigational studies, the ability to treat a
wide range of pathogens, including antibiotic-resistant strains of
bacteria (including MRSA and VRE), viruses, fungi and spores; increase
blood flow to the wound site; and reduce both inflammation and pain
while assisting in faster wound closure. The company's headquarters are
in Petaluma, California, with manufacturing operations in the United
States and Latin America. More information can be found at www.oculusis.com.
Oculus Innovative Sciences, Microcyn and Microcyn Technology are
trademarks or registered trademarks of Oculus Innovative Sciences, Inc.
All other trademarks and service marks are the property of their
Oculus Innovative Sciences, Inc.
Director of Public and Investor Relations
Source: Oculus Innovative Sciences, Inc.
News Provided by Acquire Media